Geovax Labs (GOVX)

$0.18 -0.02 (-9.23%)
Market Cap 6.22M
Revenue (ttm) 3.95M
Net Income (ttm) -24.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -632.66%
Debt to Equity Ratio 0.00
Volume 3,206,649
Avg Vol 2,079,406
Day's Range N/A - N/A
Shares Out 30.06M
Stochastic %K 68%
Beta 3.67
Analysts Strong Sell
Price Target $9.62

Company Profile

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tu...

Industry: Biotechnology
Sector: Healthcare
Phone: 678 384 7220
Fax: 678 384 7281
Address:
1900 Lake Park Drive, Suite 380, Smyrna, United States
Lion0fWallSt
Lion0fWallSt Mar. 27 at 4:00 PM
Hands off the buy button bulls, we’re liquidating $CAPR and $SLS! My advice is get out before you end up like Mr. Calvin @CJ27969 ($ATOS $GOVX $GME).
3 · Reply
Waffels
Waffels Mar. 26 at 2:27 PM
$GOVX how i feel if you looking at my GOVX heeehawwwww
0 · Reply
DeezNuttz
DeezNuttz Mar. 26 at 12:31 PM
$GOVX
0 · Reply
Brooklyn001
Brooklyn001 Mar. 25 at 6:53 PM
$GOVX Good news on progress with their proprietary Monkeypox vaccine. GeoVax $GOVX is developing continuous cell-line production rather than traditional egg-based methods. When you do some research on the market potential, there are these major factors: Mpox outbreaks have expanded globally Vaccine supply has been limited Strategic stockpiles were depleted during the 2022 outbreak. U.S. currently relies heavily on a foreign supplier for MVA vaccines. www.geovax.com/investors/press-releases/geovax-provides-update-on-geo-mva-program Looks like there are some near term catalysts coming up--- "GeoVax announced that GEO-MVA clinical supplies have completed the required release testing and final release of the product for clinical use is scheduled for early April. Upon final release, sufficient clinical material will be available to fully support the planned immune bridging study designed in accordance with guidance from the European Medicines Agency (EMA)."
0 · Reply
Finanz
Finanz Mar. 25 at 6:18 PM
$GOVX GOVX news today on the Phase 3 vaccine study Moving to Phase 3 is good news. Geovax's 's GEO-MVA is being developed to help close a critical gap in global vaccine readiness. Recent Mpox outbreaks, along with changing epidemiological dynamics, have highlighted the ongoing need for stronger preparedness measures, including greater vaccine production capacity and a more diverse network of vaccine suppliers, especially domestic supplies like GOVX. Currently, the supply of MVA-based vaccines is largely dependent on a single commercial manufacturer n Europe, leaving minimal redundancy for a platform regarded as essential for protection against both mpox and smallpox (experiencing an increase in cases recently. GOVX could benefit in the government's interest in stockpiling and strategic reserve programs https://www.streetinsider.com/Corporate+News/GeoVax+advances+mpox+vaccine+program+toward+phase+3+study/26214380.html
0 · Reply
Waffels
Waffels Mar. 25 at 4:28 PM
$GOVX i always thought great thing about this stock. if you look at it it is cute, but not as a puppy. this is a stock not a puppy🐶
0 · Reply
DeezNuttz
DeezNuttz Mar. 25 at 2:29 PM
$GOVX
0 · Reply
UltimateRampageBulls
UltimateRampageBulls Mar. 24 at 10:35 PM
If you're looking to catch some of the big runners early and hate chasing the tops and losing .. The group below is a great group to Join - banked on many of their calls. Best Free room i know👇🔥 Been buying some $TNXP $GOVX $MVST $WOLF
0 · Reply
Waffels
Waffels Mar. 24 at 3:42 PM
$GOVX I was always hero as batman is... Severin was bane. but rest assured he was defeated
0 · Reply
DeezNuttz
DeezNuttz Mar. 24 at 2:01 AM
$GOVX
0 · Reply
Latest News on GOVX
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent

Dec 9, 2024, 9:00 AM EST - 1 year ago

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

Nov 26, 2024, 9:00 AM EST - 1 year ago

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 4:00 PM EST - 1 year ago

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

Nov 5, 2024, 9:00 AM EST - 1 year ago

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Oct 2, 2024, 9:00 AM EDT - 1 year ago

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

GeoVax to Participate in Upcoming Investor Conferences in September

Sep 3, 2024, 9:00 AM EDT - 1 year ago

GeoVax to Participate in Upcoming Investor Conferences in September

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

Aug 28, 2024, 8:59 PM EDT - 1 year ago

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

GeoVax's stock slides 20% after company raises $8.5 million in stock sale

Aug 20, 2024, 8:09 AM EDT - 1 year ago

GeoVax's stock slides 20% after company raises $8.5 million in stock sale

GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market

Aug 20, 2024, 7:45 AM EDT - 1 year ago

GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOSS IMRN

GeoVax's stock soars 54% to lead rally in companies developing mpox treatments

Aug 19, 2024, 7:30 AM EDT - 1 year ago

GeoVax's stock soars 54% to lead rally in companies developing mpox treatments

GeoVax to Present at the Emerging Growth Conference on August 21, 2024

Aug 15, 2024, 9:00 AM EDT - 1 year ago

GeoVax to Present at the Emerging Growth Conference on August 21, 2024

Mpox outbreak: 5 stocks to watch out for as the emergency unfolds

Aug 15, 2024, 8:36 AM EDT - 1 year ago

Mpox outbreak: 5 stocks to watch out for as the emergency unfolds

EBS SIGA

GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

Aug 8, 2024, 9:00 AM EDT - 1 year ago

GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 6, 2024, 4:00 PM EDT - 1 year ago

GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

Jul 31, 2024, 10:15 AM EDT - 1 year ago

Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

Apr 4, 2024, 12:30 PM EDT - 2 years ago

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

Mar 28, 2024, 9:00 AM EDT - 2 years ago

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

GeoVax to Present at the 36th Annual Roth Conference

Mar 12, 2024, 9:00 AM EDT - 2 years ago

GeoVax to Present at the 36th Annual Roth Conference

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System

Mar 6, 2024, 9:00 AM EST - 2 years ago

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

Feb 29, 2024, 4:00 PM EST - 2 years ago

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024

Feb 22, 2024, 9:00 AM EST - 2 years ago

GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024

GeoVax to Present at the 2024 BIO CEO & Investor Conference

Feb 19, 2024, 9:00 AM EST - 2 years ago

GeoVax to Present at the 2024 BIO CEO & Investor Conference

GeoVax Announces Multiple Patent Issuances and Allowances

Feb 13, 2024, 9:00 AM EST - 2 years ago

GeoVax Announces Multiple Patent Issuances and Allowances

GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster

Feb 6, 2024, 9:00 AM EST - 2 years ago

GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Jan 29, 2024, 9:00 AM EST - 2 years ago

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

Jan 8, 2024, 9:00 AM EST - 2 years ago

GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology

GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients

Jan 4, 2024, 9:00 AM EST - 2 years ago

GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients

GeoVax Announces Issuance of Malaria Vaccine Patent

Jan 3, 2024, 9:00 AM EST - 2 years ago

GeoVax Announces Issuance of Malaria Vaccine Patent

GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024

Dec 27, 2023, 9:00 AM EST - 2 years ago

GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024

GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox

Dec 19, 2023, 9:00 AM EST - 2 years ago

GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox

GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress

Nov 30, 2023, 4:30 PM EST - 2 years ago

GeoVax Hemorrhagic Fever Vaccine Data Presented at World Vaccine Congress

GeoVax to Participate in Upcoming December Investor Events

Nov 29, 2023, 9:00 AM EST - 2 years ago

GeoVax to Participate in Upcoming December Investor Events

GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress

Nov 28, 2023, 9:00 AM EST - 2 years ago

GeoVax COVID-19 Vaccine Clinical Data Presented at World Vaccine Congress

Progress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023

Nov 14, 2023, 9:00 AM EST - 2 years ago

Progress on GeoVax's Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023

GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 4:00 PM EST - 2 years ago

GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update

GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Oct 30, 2023, 9:00 AM EDT - 2 years ago

GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

GeoVax to Participate in Upcoming November Investor and Industry Events

Oct 25, 2023, 9:00 AM EDT - 2 years ago

GeoVax to Participate in Upcoming November Investor and Industry Events

GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities

Oct 24, 2023, 9:00 AM EDT - 2 years ago

GeoVax Update: Clinical and Operational Progress Toward Transformative Opportunities

GeoVax Receives Notice of Allowance for Marburg Vaccine Patent

Oct 9, 2023, 9:00 AM EDT - 2 years ago

GeoVax Receives Notice of Allowance for Marburg Vaccine Patent

GeoVax Receives Notice of Allowance for HIV Vaccine Patent

Oct 5, 2023, 9:00 AM EDT - 2 years ago

GeoVax Receives Notice of Allowance for HIV Vaccine Patent

GeoVax to Participate in Upcoming October Investor and Industry Events

Sep 27, 2023, 9:00 AM EDT - 2 years ago

GeoVax to Participate in Upcoming October Investor and Industry Events

GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference

Sep 20, 2023, 9:00 AM EDT - 2 years ago

GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference

GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients

Sep 19, 2023, 9:00 AM EDT - 2 years ago

GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients

GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 12, 2023, 9:00 AM EDT - 2 years ago

GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference

GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster

Sep 11, 2023, 9:00 AM EDT - 2 years ago

GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster

GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 31, 2023, 9:00 AM EDT - 2 years ago

GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GeoVax to Present at the Emerging Growth Conference on September 6, 2023

Aug 29, 2023, 9:00 AM EDT - 2 years ago

GeoVax to Present at the Emerging Growth Conference on September 6, 2023

GeoVax Receives Notice of Allowance for Malaria Vaccine Patent

Aug 28, 2023, 9:00 AM EDT - 2 years ago

GeoVax Receives Notice of Allowance for Malaria Vaccine Patent

GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

Aug 10, 2023, 9:00 AM EDT - 2 years ago

GeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

Lion0fWallSt
Lion0fWallSt Mar. 27 at 4:00 PM
Hands off the buy button bulls, we’re liquidating $CAPR and $SLS! My advice is get out before you end up like Mr. Calvin @CJ27969 ($ATOS $GOVX $GME).
3 · Reply
Waffels
Waffels Mar. 26 at 2:27 PM
$GOVX how i feel if you looking at my GOVX heeehawwwww
0 · Reply
DeezNuttz
DeezNuttz Mar. 26 at 12:31 PM
$GOVX
0 · Reply
Brooklyn001
Brooklyn001 Mar. 25 at 6:53 PM
$GOVX Good news on progress with their proprietary Monkeypox vaccine. GeoVax $GOVX is developing continuous cell-line production rather than traditional egg-based methods. When you do some research on the market potential, there are these major factors: Mpox outbreaks have expanded globally Vaccine supply has been limited Strategic stockpiles were depleted during the 2022 outbreak. U.S. currently relies heavily on a foreign supplier for MVA vaccines. www.geovax.com/investors/press-releases/geovax-provides-update-on-geo-mva-program Looks like there are some near term catalysts coming up--- "GeoVax announced that GEO-MVA clinical supplies have completed the required release testing and final release of the product for clinical use is scheduled for early April. Upon final release, sufficient clinical material will be available to fully support the planned immune bridging study designed in accordance with guidance from the European Medicines Agency (EMA)."
0 · Reply
Finanz
Finanz Mar. 25 at 6:18 PM
$GOVX GOVX news today on the Phase 3 vaccine study Moving to Phase 3 is good news. Geovax's 's GEO-MVA is being developed to help close a critical gap in global vaccine readiness. Recent Mpox outbreaks, along with changing epidemiological dynamics, have highlighted the ongoing need for stronger preparedness measures, including greater vaccine production capacity and a more diverse network of vaccine suppliers, especially domestic supplies like GOVX. Currently, the supply of MVA-based vaccines is largely dependent on a single commercial manufacturer n Europe, leaving minimal redundancy for a platform regarded as essential for protection against both mpox and smallpox (experiencing an increase in cases recently. GOVX could benefit in the government's interest in stockpiling and strategic reserve programs https://www.streetinsider.com/Corporate+News/GeoVax+advances+mpox+vaccine+program+toward+phase+3+study/26214380.html
0 · Reply
Waffels
Waffels Mar. 25 at 4:28 PM
$GOVX i always thought great thing about this stock. if you look at it it is cute, but not as a puppy. this is a stock not a puppy🐶
0 · Reply
DeezNuttz
DeezNuttz Mar. 25 at 2:29 PM
$GOVX
0 · Reply
UltimateRampageBulls
UltimateRampageBulls Mar. 24 at 10:35 PM
If you're looking to catch some of the big runners early and hate chasing the tops and losing .. The group below is a great group to Join - banked on many of their calls. Best Free room i know👇🔥 Been buying some $TNXP $GOVX $MVST $WOLF
0 · Reply
Waffels
Waffels Mar. 24 at 3:42 PM
$GOVX I was always hero as batman is... Severin was bane. but rest assured he was defeated
0 · Reply
DeezNuttz
DeezNuttz Mar. 24 at 2:01 AM
$GOVX
0 · Reply
Waffels
Waffels Mar. 23 at 6:09 PM
$GOVX severin was my son… and GOVX was his mother…. we were very intimiate…..
0 · Reply
Ironclad_Trading
Ironclad_Trading Mar. 22 at 8:03 PM
Is $GOVX the Next Big Short Squeeze? Armistice Capital Just Took 8% - Ea... https://youtu.be/eTFEG4-PMmo?si=YrQJ5zaDdcGunF1z via @YouTube #GOVX #ShortSqueeze #Biotech
0 · Reply
Ironclad_Trading
Ironclad_Trading Mar. 22 at 6:34 PM
$GOVX — Video Tonight Make sure to subscribe, follow, like, and share! Turn on notifications so you don’t miss this special video covering GeoVax and its #earnings #guidance. It’s under 30 minutes, so grab your coffee and a snack—you won’t want to miss it! #Geovax
0 · Reply
Brooklyn001
Brooklyn001 Mar. 20 at 8:30 PM
$GOVX Geovax $GOVX Looking like there is a basebuilding going on ...again Last time, it ran 40%. And the recent news is getting attention in the medical world. https://finance.yahoo.com/news/geovax-announces-european-society-medicine-130000799.html
0 · Reply
DavidScott
DavidScott Mar. 20 at 8:07 PM
$LIDR $ANGX $GOVX $NMAX $WNW = Great job bulls! It was a nice week, even amidst these choppy market conditions. These were our team's best trades! We are bullish and expecting even more action on these names again going into Monday. If you need any guidance or a mentor, then feel free to join our team anytime! ✅🤝 Have a great weekend everyone! 🎉
0 · Reply
GuruChartist
GuruChartist Mar. 19 at 1:07 PM
$GOVX Chart looks oversold again. When the RSI is under 30, it is close to -- or at-- a bottom.
0 · Reply
vlentini
vlentini Mar. 18 at 6:47 PM
$GOVX Diretto a zero,siamo stati truffati!
0 · Reply
Beanie_Mojo
Beanie_Mojo Mar. 17 at 1:40 PM
$GOVX & $SOAR 🗑️🗑️ Going backwards. 🚽🚽 💩 🪠
0 · Reply
DeezNuttz
DeezNuttz Mar. 17 at 1:17 PM
$GOVX
0 · Reply
ZacksResearch
ZacksResearch Mar. 13 at 1:18 PM
$GOVX highlights GEO-CM04S1 as a next-generation COVID-19 vaccine designed for immunocompromised patients in a new peer-reviewed publication. The dual-antigen (Spike + Nucleocapsid) MVA-based vaccine is designed to generate broader immunity and strong CD4+ and CD8+ T-cell responses. Early Phase 2 data shows durable immune responses even in patients with weakened immune systems — a population of more than 400M globally that often responds poorly to current vaccines. Price target breakdown here 👇 https://www.zacks.com/stock/research/GOVX/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-37277&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_37277
0 · Reply
Finanz
Finanz Mar. 12 at 3:29 AM
$GOVX https://finance.yahoo.com/news/geovax-initiates-outreach-regarding-future-130000548.html
0 · Reply
DeezNuttz
DeezNuttz Mar. 11 at 1:05 PM
$GOVX
0 · Reply